Clinical Trials Browser

Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT02260414 2017-05-11

METRO B

Phase 2 Completed

19 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01471067 2017-04-28

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Phase 1 Completed

33 enrolled

LymphoidMyeloidOther hematologic neoplasm

Pathologic Complete Response, Histiocytosis, Langerhans-Cell, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Philadelphia Chromosome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

35 enrolled 11 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00590941 2013-05-16

Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma

Phase NA Completed

52 enrolled

Lymphoid

Lymphoma

Clinical Trials

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

BIOLYMPH2020

DeLPHy

PET Imaging of Subjects Using 124I-PU-AD

ExoReBLy

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

METRO B

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma